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ABSTRACT
Aims To perform a quantitative systematic review of observational studies on the risk of stroke associated with the use of individual NSAIDs.
Methods and results Searches were conducted using the Medline database within PubMed (1990–2008). Observational cohort or case–
control studies were eligible if reported on the risk of cardiovascular events associated with individual NSAIDs versus the nonuse of NSAIDs.
We found 3193 articles, in which 75were eligible for review and abstraction. Of the 75 articles, 6 reported relative risk (RR) of stroke. Data were
abstracted into a database using a standardized entry form. Two authors assessed study quality, and discrepancies were resolved by consensus.
The pooled RR of all subtypes of incident stroke was increased with the current use of rofecoxib (RR= 1.64, 95% CI = 1.15–2.33) and
diclofenac (RR= 1.27, 95% CI = 1.08–1.48). The pooled estimates for naproxen, ibuprofen, and celecoxib were close to unity. The risk of
ischemic stroke was also increased with rofecoxib (RR= 1.82, 95% CI = 1.09–3.04) and diclofenac (RR= 1.20, 95% CI = 0.99–1.45). Data
were inadequate to estimate the pooled RR by dose and duration, for other individual NSAIDs or nonischemic stroke subtypes.
Conclusion This meta-analysis supports an increased risk of ischemic stroke with the current use of rofecoxib and diclofenac. Additional
studies are required to evaluate most individual NSAIDS, the effect of dose and duration, and the subtypes of stroke. Copyright © 2011 John
Wiley & Sons, Ltd.
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INTRODUCTION
The cardiovascular safety of NSAIDs is still under
scrutiny. The introduction of selective cyclooxygenase
2 (COX-2) inhibitors raised concern after patients with
rheumatoid arthritis randomized to rofecoxib experi-
enced a greater risk of acute myocardial infarction
(AMI) over those randomized to naproxen.1 A voluntary
withdrawal of rofecoxib worldwide followed the
results of the Adenomatous Polyp Prevention on
Vioxx trial showing an increased risk of cardiovascu-
lar events for rofecoxib over placebo.2 A dose-related
increased risk of cardiovascular events was also ob-
served in randomized clinical trials performed with
celecoxib,3 valdecoxib,4 and parecoxib.4 The Food
and Drug Administration stopped the Alzheimer's Dis-
ease Anti-inflammatory Prevention Trial because of an
increase in cardiovascular events in naproxen as com-
pared with placebo.5 The review of selective COX-2
inhibitors safety by the Food and Drug Administration
and the European Medicines Agency resulted in their
contraindication in patients with ischemic heart disease,
stroke, or peripheral arterial disease. The cardiovascular
safety of traditional NSAIDs was also of concern.
The syntheses of published interventional and
observational studies conclude that both selective and
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nonselective COX-2 inhibitors increase the risk of se-
rious cardiovascular events, and this risk varies across
individual NSAIDs.6–9 Results from observational
studies are consistent with those from interventional
studies regarding the effects of individual NSAIDs
on the risk of AMI. Cardiovascular toxicity associated
with selective COX-2 and some traditional NSAIDs is
mediated through a common mechanism involving the
inhibition of COX-2-dependent prostacyclin. Most of
NSAIDs are functionally selective for COX-2 at thera-
peutic doses.10 With the exception of aspirin, the only
NSAID that lacks functional COX-2 selectivity in plate-
lets is naproxen, and this is seen only at high doses in
some individuals.11 Stroke is one of the leading causes
of morbidity and mortality worldwide. Any potential
increase in the risk of stroke, although low, associated
with the use of NSAIDs will have an important health
effect at the population level. However, there is limited
evidence from interventional studies on the effect of
individual NSAIDs on the risk of stroke. We synthe-
sized the evidence from observational studies to assess
the potential differential effects of individual NSAIDs
on the risk of stroke.
The Safety of Nonsteroidal Anti-inflammatory
Drugs (SOS) project is a research and development
project funded by the Health Area of the European
Commission under the VII Framework Programme.
One of the first steps of this project was a quantitative
systematic literature review of observational studies to
assess the risk of cardiovascular events associated with
the use of NSAIDs for planning future research. We
summarized first the estimates of the effect of individ-
ual NSAIDs on the risk of stroke from published
observational studies. We followed the PRISMA guide-
lines for reports of systematic reviews (http//www.
prisma-statement.org/).
METHODS
Literature search
We performed a systematic literature search on cardio-
vascular events in the Medline database within
PubMed using free text search terms and medical sub-
ject headings for stroke, myocardial infarction, heart
failure, left ventricular dysfunction, acute coronary
syndrome, sudden cardiac death, and nonsteroidal
anti-inflammatory agents. We examined references of
relevant articles for additional sources.
Eligible studies for review were observational co-
hort or case–control studies published in English in
peer-reviewed journals between January 1, 1990, and
November 30, 2008. The initial broad search identified
3203 articles, but 3128 articles did not meet the inclu-
sion criteria for study design or study medications. The
main reasons for exclusion were partial study reports
(letters, comments, and abstracts), noncomparative ob-
servational studies, and studies evaluating inappropriate
end points or exposures. The review of the remaining 75
studies led to the exclusion of 20 studies, and 55 articles
reported results on the use of individual NSAIDs and
cardiovascular end points (acute coronary syndrome,
36; stroke, 812–19; heart failure, 6; death, 2; and com-
posite end point, 8). The details of article identification
and selection processes are in Figure 1.
Studies for inclusion in the present meta-analysis were
required to provide measures of association comparing
the risk of acute ischemic and/or hemorrhagic stroke be-
tween the users of individual NSAIDs and the nonusers.
Two studies16,17 were excluded because they used
other reference categories. Data were abstracted into
a database using a standardized entry form.
Assessment of study quality
We used the Newcastle–Ottawa Scale (NOS)20 to
evaluate study quality components for cohort or
case–control studies, as recommended by the
Cochrane Non-Randomized Studies Methods Work-
ing Group. The NOS quality scoring focuses on the se-
lection of study groups, the comparability between the
study groups, and the ascertainment of the exposure in
case–control studies or the outcome in cohort studies.
Two investigators (NR and CV) performed the quality
evaluation, and discordances were solved by
consensus.
Statistical analysis
We pooled the ORs or relative risks (RR), for each in-
dividual NSAID estimated in each study. According to
the data available in each study, we conducted pooled
prespecified analyses for incident and recurrent cases
combined, incident cases only, prevalent and new
users of each individual NSAID combined, and new
users only. We estimated pooled RRs separately for
overall stroke and ischemic stroke. Data were insuffi-
cient to estimate the effect of dose and duration for in-
dividual NSAIDs.
We estimated pooled RRs and 95% CI for the effect
of each NSAID with at least three independent point
estimates available by weighting study estimates by
the inverse of the variance and estimating linear pre-
dictors for the log effect measure.21 Fixed and random
effects were calculated. Forest plots were constructed
on the basis of the pooled RR estimated from the ran-
dom effects models. Heterogeneity between studies
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was assessed by graphical inspections of the forest
plots and by Cochran's w2 test of homogeneity and
Tau2 for random effect models. The Higgins I2 statis-
tic was used to describe the percentage of between-
study variability in effect estimates that is attributable
to true heterogeneity rather than chance. Publication
bias was examined by visual evaluation of funnel
plots. The analysis was conducted using Review Man-
ager (RevMan) (Version 5.0.22 Copenhagen; The
Nordic Cochrane Centre, The Cochrane Collaboration,
2009).
RESULTS
Characteristics and quality of included studies
Table 1 describes the main features of the six included
studies in the meta-analysis, conducted in selected US
and European populations.12–15,18,19 Four studies were
cohort studies; two were nested case–control studies.
Five studies used data collected in electronic data-
bases. One prospective cohort study of elderly was
supplemented by electronic drug dispensing and hos-
pital discharge data. Two studies used both outpatient
and hospital diagnoses.13,15 Two studies were re-
stricted to ischemic stroke13,19; four studies also in-
cluded hemorrhagic stroke, including or excluding
subarachnoid hemorrhage (SAH). Overall, four studies
provided estimates for ischemic stroke.13–15,19 Four
studies were restricted to the evaluation of incident
events.
Naproxen, ibuprofen, diclofenac, celecoxib, and
rofecoxib were the most frequently evaluated. The cur-
rent use of the individual NSAID was defined as the
use at the index date or the use during a variable time
window before the index date. Information on dose,
duration, and aspirin use was scarce in these studies.
The studies had good quality: four studies scored the
maximum NOS score for selection of subjects.13–15,18
All studies scored the maximum for comparability
and for the ascertainment of outcome (cohort studies)
or exposure (case–control studies).
Meta-analysis
Table 2 shows the results of the pooled analysis for all
types of stroke and for the studies of incident strokes.
Heterogeneity between studies was present for all indi-
vidual NSAIDs except diclofenac and was reduced in
Studies identified with PubMed search strategy on cardiovascular events
n = 3,193 
Studies excluded after reviewing titles and abstracts*
n = 3,128
Studies included in the meta-analysis for Stroke 
n = 6
Full-text articles reviewed
n = 75
Studies retrieved through cross-referencing
n = 10
Studies excluded, n = 20 
 Not cohort or case-control study,  
 n = 5 
 External or no comparator, n = 1 
 Estimates or sufficient data to 
 calculate measures of association  
 not available for individual  
 NSAIDs, n = 13 
 Retracted, n = 1 
Studies excluded, n = 49 
 CV endpoints other than Stroke, 
n = 47 
Other reference category, n = 2
Studies included for data abstraction
n = 55
Figure 1. Flow chart of identification and selection of studies; *main reasons for exclusions included the following: a) Not a cohort or a case-control study;
b) No fully study report; c) Non-comparative studies or studies with external comparisons groups; d) Estimates or sufficient data to calculate measures of
association were not available for individual NSAIDs; e) Studies conducted in hospitalized or institutionalized patients; f) Inappropriate endpoint
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Table 2. RR of stroke associated with naproxen, ibuprofen, diclofenac, celecoxib, and rofecoxib use compared with no NSAID use
Author (no. studies) Cases (N)
Naproxen RR
(95% CI)
Ibuprofen RR
(95% CI)
Diclofenac RR
(95% CI)
Celecoxib RR
(95% CI)
Rofecoxib RR
(95% CI)
All types of stroke
(n= 6)*
Abraham et al.12 NR 2.00 (1.49–2.70) 1.70 (1.24–2.32) NA 1.70 (1.14–2.54) 3.00 (2.04–4.42)
Andersohn et al.13† 684 1.16 (0.80–1.70) 1.12 (0.91–1.37) 1.32 (1.10–1.57) 1.07 (0.79–1.44) 1.71 (1.33–2.18)
Bak et al.14† 158 0.70 (0.44–1.13) 1.30 (1.03–1.64) 1.10 (0.70–1.70) NA NA
Haag et al.15† 52 2.63 (1.47–4.72) 1.47 (0.73–3.00) 1.60 (1.00–2.57) NA 3.38 (1.48–7.74)
Roumie et al.18† 574 0.94 (0.80–1.11) 0.88 (0.73–1.06) 0.94 (0.59–1.49) 1.04 (0.87–1.23) 1.28 (1.06–1.53)
Solomon et al.19 1904 0.83 (0.67–1.04) 0.95 (0.78–1.16) 0.98 (0.75–1.29) 1.00 (0.92–1.09) 1.15 (1.04–1.26)
Pooled RR (95% CI)
Random effects 1.19 (0.85–1.65) 1.15 (0.95–1.39) 1.17 (0.98–1.40) 1.08 (0.93–1.25) 1.70 (1.25–2.31)
Fixed effects 1.05 (0.94–1.17) 1.08 (0.98–1.19) 1.20 (1.05–1.36) 1.03 (0.96–1.10) 1.27 (1.18–1.38)
Heterogeneity (P) <0.00001 0.004 0.21 0.09 <0.00001
Incident stroke (n= 4 )†
Pooled RR (95% CI)
Random effects 1.14 (0.76–1.69) 1.10 (0.89–1.36) 1.27 (1.08–1.48) 1.04 (0.90–1.21) 1.64 (1.15–2.33)
Fixed effects 1.00 (0.87–1.15) 1.06 (0.95–1.20) 1.27 (1.10–1.47) 1.04 (0.90,1.21) 1.45 (1.26–1.68)
Heterogeneity (P) 0.003 0.05 0.37 0.85 0.02
Results from published studies and pooled estimates, overall analysis, and studies of incident stroke.
NR, not reported; NA, not applicable.
*All types of stroke, incident plus prevalent cases of all subtypes of stroke.
†Denotes studies restricted to incident events.
Figure 2. Forest plots of the risk of incident stroke, ischemic and hemorrhagic, associated with current use of naproxen, ibuprofen, diclofenac and rofecoxib
relative to nonuse; results from published studies (n=4) and pooled estimates by random effects
stroke and nsaids 1229
Copyright © 2011 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2011; 20: 1225–1236
DOI: 10.1002/pds
the analysis of incident stroke. Figure 2 displays indi-
vidual study results and pooled estimates for each indi-
vidual NSAID on the risk of incident stroke. The
pooled RRs were 1.64 (95% CI = 1.15–2.33) for rofe-
coxib and 1.27 (95% CI = 1.08–1.48) for diclofenac.
The pooled estimates for naproxen, ibuprofen, and cel-
ecoxib were close to unity. Estimates for celecoxib
were based on only two studies (Table 2).
The apex in the funnel plot for all types of stroke is
pointing up around a RR of 1.3 (Figure 3). Higher
estimates for naproxen and rofecoxib were observed
in the smallest study.15 No small studies reporting a
reduction on the risk of stroke were published, which
might indicate some publication bias.
Pooled RR estimates by stroke subtype
Figure 4 shows the forest plots of the pooled esti-
mates of studies reporting the risk of ischemic stroke
associated using individual NSAIDs compared
with the nonuse of NSAIDs. The pooled RRs were
1.82 (95% CI = 1.09–3.04) for rofecoxib and 1.20
(95% CI = 0.99–1.45) for diclofenac, similar to those
observed in the analysis of all stroke types combined.
Only one study evaluated separately the risk of
hemorrhagic stroke; the RRs associated with each
individual NSAID were similar for intracerebral
hemorrhage and ischemic stroke.14 This study also
estimated SAH risk separately from the overall analy-
sis, but only for all NSAIDs combined (RR= 1.2, 95%
CI = 0.7–2.1).14
Subgroup analyses
Only two studies estimated the effect of dose and du-
ration (Table 3).13,18 One study reported a tendency
to a higher risk of ischemic stroke with the high doses
of rofecoxib and etoricoxib but not celecoxib.13 The
other study found no increased risk of stroke by
dose for celecoxib, ibuprofen, naproxen, diclofenac,
or indomethacin.18 For rofecoxib and valdecoxib, most
stroke events were observed in the low-dose group.
Rofecoxib was associated with an increased risk of
stroke in short- and long-term use, with higher risk
associated with longer duration (Table 3).13 An in-
creased risk of stroke associated with either valdecoxib
or etoricoxib was observed in both short- and long-
term users, using 90 days as the cutoff point. CIs in-
cluded the null value (Table 3).
Two studies evaluated the effect in the new users of
individual NSAIDs.18,19 One of the studies reported
that the RR associated with each individual NSAID
was slightly higher in new users than that obtained
for all users.18
On the basis of two studies, the pooled RR for indo-
methacin use was 1.25 (95% CI = 0.94–1.68) (data not
shown). One study reported an increased risk of inci-
dent stroke associated with valdecoxib use (RR= 1.41,
95% CI = 1.04–1.91) and another study with etoricoxib
use (RR= 2.38, 95% CI = 1.10–5.13).13,18
No studies evaluated the risk of stroke associated
with the concomitant use of NSAIDs and aspirin.
One study reported that 39% of the cases of ische-
mic stroke and 22% of controls used low doses of
aspirin. However, the investigators did not evaluate
the effect by aspirin use13; the estimates were simi-
larly elevated for rofecoxib and etoricoxib in patients
with or without cardiovascular disease, atrial fibrilla-
tion, or hypertension.
Sensitivity analysis
We performed a subanalysis excluding the study that
reported high RRs for naproxen and rofecoxib, but het-
erogeneity across studies was still present.15 We also
excluded the study that included only men and defined
current exposure using a larger time window than that
used in other studies.12 This exclusion reduced hetero-
geneity between studies and resulted in a pooled RR
for rofecoxib of 1.32 (95% CI = 1.07–1.62).
DISCUSSION
Our meta-analysis, including more than 14,375 stroke
events, that is, 10,163 ischemic, 1403 haemorrhagic
(intracerebral hemorrhage or SAH), and 273 of un-
specified origin, supports an elevated risk of ischemic
stroke associated with the current use of rofecoxib
(RR= 1.82, 95% CI = 1.09–3.04) and diclofenac
(RR= 1.20, 95% CI = 0.99–1.45) of similar magnitude
Figure 3. Funnel plot; RR of stroke for individual NSAIDs compared
with NSAID nonuse (n=6 studies); RR is plotted on the horizontal axis
and an estimate of its precision, SE (log RR), on the vertical axis
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to that estimated in the prior meta-analyses of observa-
tional studies assessing the risk of AMI.6,8 Pooled RRs
estimated for naproxen, ibuprofen, and celecoxib are
also consistent with those previously estimated for
AMI.
To our knowledge, this is the first meta-analysis
of observational studies assessing the risk of stroke
associated with use of individual NSAIDs compared
with the nonuse of NSAIDs. Our meta-analysis was
limited by the low number of published studies ful-
filling the inclusion criteria. Only summary esti-
mates for the most frequently used NSAIDs across
the studied populations were obtained, and in some
instances, these estimates might have been heavily
influenced by the imprecise risk estimates in the in-
dividual studies.
Heterogeneity between studies was present for all
individual NSAIDs except diclofenac. We evaluated
the potential sources of heterogeneity instead of not
pooling the data from these studies. Estimates were
more homogenous between studies when restricting
the analysis to incident events only or to ischemic
subtype only. We calculated pooled effect estimates
by both fixed and random effect models. Random
effects models are recommended in the context of
substantial heterogeneity; however, fixed effect
models might be preferable when the number of
studies is small.
The evidence on the effect of individual NSAIDs on
the risk of stroke continues to be limited. The Adeno-
matous Polyp Prevention on Vioxx trial found a risk of
ischemic stroke for rofecoxib twice that for placebo.2
A meta-analysis of randomized clinical trials reported
a moderately increased risk of vascular events associ-
ated with selective COX-2 inhibitors, largely attribut-
able to a twofold increased risk of AMI.7 The high-
dose regimens of some traditional NSAIDs such as
diclofenac and ibuprofen were associated with similar
excess risk of vascular events. However, the specific
analysis for stroke failed to show an increased risk ef-
fect of either selective COX-2 inhibitors or traditional
NSAIDs, likely because of the small number of events.
In 121 clinical trials, 70 stroke events occurred in
18,490 person-years of selective COX-2 inhibitor
Figure 4. Forest plots of the risk of ischemic stroke associated with current use of naproxen, ibuprofen, diclofenac and rofecoxib relative to nonuse; results
from published studies (n=4) and pooled estimates by random effects
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exposure compared with 53 events in 12,639 person-
years in placebo. In fact, the upper limit of the 95%
CI for the RR was 1.47.
More recently, Trelle et al.22 have published a meta-
analysis of large randomised controlled trials of
NSAIDs. For stroke, 26 trials provided data with 337
observed events. Most of the individual NSAIDs eval-
uated presented a pooled rate ratio greater than 1 as
compared with placebo. However, the 95% CIs of
these estimates of risk were very wide, including the
unity. Interestingly, ibuprofen, diclofenac, etoricoxib,
and lumiracoxib showed the highest pooled estimates,
whereas rofecoxib and celecoxib presented the smal-
lest estimates of risk. The authors acknowledged,
among some of the limitations, that the quality of the
reported safety data from these trials was suboptimal.
The studies in our meta-analysis included broad
study populations, although the US studies were all
in elderly persons, and in one study, patients with
baseline life-threatening conditions or neoplasms were
excluded.18 Most the studies included both the new
and the prevalent users of NSAIDs. The inclusion of
prevalent users can introduce bias caused by the
underascertainment of events that occur after the start
of the therapy but before the start of the study (which
may lead to depletion of susceptibles) and by the in-
ability to control for risk factors that may be modified
by the study drugs.23,24 Two studies provided RRs in
new users18,19; one of them reporting a higher RR of
stroke in new users than in all users.18
Potential biases secondary to the modification of
risk factors by the study drugs can be avoided by
measuring these factors at the beginning of the ther-
apy when they are not influenced by the treatment.
Hypertension can be considered a causal intermedi-
ate factor because it can be an effect of NSAIDs
and is a strong risk factor for stroke. Thus, adjust-
ing for hypertension or for the use of concurrent
hypertensive medications during the follow-up could
result in the underestimation of the RR.25 Most of the
studies adjusted for hypertension only at baseline.
Two studies conducted analysis stratified by the pres-
ence or absence of hypertension, but no effect modifi-
cation was observed.13,19
The incomplete ascertainment of cases might
potentially affect the results of these studies, but this
misclassification should be nondifferential if unrelated
with the exposure to NSAIDs. Most studies evaluated
both hemorrhagic and ischemic stroke, but separate
results were available only for ischemic stroke. Stroke
is a complex condition, with different pathophysiology
for and multiple etiologies within each subtype. In
the studies that performed validation, the positiveTa
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predictive value for overall stroke tended to be high
(97%). Assessing incident cases might be an issue
without performing complete validation26; however,
a major challenge is to differentiate between hemor-
rhagic and ischemic stroke, which is important for
NSAID safety studies because the mechanism for each
condition is different.
It has been reported that the extent of COX-2-
dependent prostacyclin inhibition may represent
an independent key determinant of the increased
thrombotic risk with NSAIDs in the presence of
an insufficient reduction of platelet COX-1 activity
(<95%) to inhibit platelet function.11 Individual
NSAIDs with a degree of COX-2 inhibition less than
90% at therapeutic concentrations (ibuprofen, meloxi-
cam, celecoxib, and etoricoxib) have been associated
with an RR of AMI of 1.18 (95% CI = 1.02–1.38),
whereas those with greater COX-2 inhibition (rofe-
coxib, diclofenac, indomethacin, and piroxicam) had
an RR of 1.60 (95% CI = 1.41–1.81).27 The pooled
estimates on the risk of stroke from our meta-analysis
across the individual NSAIDs evaluated are consistent
with this pattern.
Because NSAIDs are a chemically heterogeneous
group of agents, the use of each compound might also
translate into a differential effect not only on the risk of
thrombotic events but also on hemorrhagic events. Re-
cently, a study reported separately results on the risk of
ischemic and hemorrhagic stroke.28 However, this study
did not meet our inclusion criteria.
Recall bias is not an issue in any of the included
studies because all assessed exposure by electronic
prescriptions. No study captured the use of over-the-
counter drugs; therefore, the effect of aspirin used for
cardioprotection on the risk of stroke is not available.
All of the studies described the baseline characteristic
and risk profiles of the users of each individual
NSAID. One study used disease risk scores to summa-
rize potential confounders into a single multivariable
model that predicts the risk of disease on the basis of
measured covariates.29 In addition to age and sex, the
most frequently considered covariates were transient is-
chemic attack, atrial fibrillation, heart failure, myocardial
infarction, coronary heart disease, hypercholesterolemia,
hypertension, diabetes, and arthritis.
There is still debate on whether the reduction of
stroke incidence associated with statin use is due to
the cholesterol-reduction effect only or to the pleiotro-
pic effects of statins also, such as improved endothelial
function, decreased platelet aggregability, and reduced
vascular inflammation. Lipid-lowering drugs were
considered in all of the studies except one that adjusted
the individual's levels of total serum cholesterol.15
Residual confounding might be an issue in those
studies that failed to systematically record some factors
such as smoking, physical activity, socioeconomic sta-
tus, or body mass index. In one of the studies, the users
of COX-2 inhibitors were more likely than the nonu-
sers to have a lower educational attainment, obesity,
and currently smoke in a separate survey performed
on the members of the source population.19 Investiga-
tors calculated that these differences resulted in a 2%
bias away from the null. Therefore, although all of
the studies in this meta-analysis might be affected
by unmeasured confounding and by some misclassi-
fication of over-the-counter NSAID use, the bias was
likely not differential between individual drugs.
Bias by contraindication to cardiovascular high-
risk patients would be relatively minor because none
of the studies included time after the withdrawal of
rofecoxib.
Protopathic bias may occur if the exposure to the
drug of interest started, stopped, or changed because
of an unrecognized initial manifestation of the disease
under study.30 One study reported the presence of proto-
pathic bias in patients with stroke to be more prominent
in those with SAH. In these patients, sentinel headache
triggered the prescription of NSAIDs.14 None of the
studies assessed migraine as potential confounder.31
One of the potential sources of heterogeneity can be
the patterns of use of each individual NSAIDs across
the study populations. In studies performed in the
United States, diclofenac was less frequently used than
in studies performed in European populations. This
might have resulted in some underestimation of the risk
of stroke associated with diclofenac use because of the
imprecise estimates of risk obtained from these studies.
In addition, we were not able to estimate pooled RRs
stratified by dose and duration. Results provided in indi-
vidual studies were limited by the low numbers of sub-
jects exposed to high doses. Information from the few
individual studies assessing the duration of use sug-
gested that the risk of stroke associated with rofecoxib
is present from the beginning of the therapy and might
be higher with durations longer than 12months.13
In conclusion, results from observational studies
in this systematic review suggest a variability of
effect on the risk of ischemic stroke across individ-
ual NSAIDs. Rofecoxib and diclofenac were associ-
ated with an increased risk of ischemic stroke com-
pared with the nonuse of NSAID. Additional
studies are needed to evaluate the risk of stroke asso-
ciated with individual NSAIDs by dose, duration,
concomitant use of aspirin, and separately for each
stroke subtype and to address the potential for resid-
ual confounding.
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KEY POINTS
• To the best of our knowledge, this is the first
meta-analysis of published results from observa-
tional studies on the risk of stroke associated
with the use of NSAIDs.
• Our results suggest a variability of effect on the
risk of ischemic stroke across individual NSAIDs;
rofecoxib and diclofenacwere associated with an in-
creased risk compared with the nonuse of NSAID.
• Additional studies are needed to evaluate the risk
of stroke associated with individual NSAIDs by
dose, duration, and concomitant use of aspirin
and separately for each stroke subtype and to ad-
dress the potential for residual confounding.
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APPENDIX A
LITERATURE SEARCH STRATEGY FOR
CARDIOVASCULAR ENDPOINTS
PubMed was searched using the following groups of
search terms, restricted to English-language publica-
tions and human subjects.
1. Pertinent, high-level medical subject headings
(MeSH) and free-text terms related to cardiovascular
events:
Stroke (hemorrhagic and ischemic), heart failure,
myocardial infarction, and associated mortality
2. Pertinent MeSH and free-text terms to identify the
relevant drugs.
3. Pertinent MesH and free-text terms related to cohort
and case–control studies.
The PubMed search terms for cardiovascular end-
points are described in the strategy below.
1. stroke [Tiab] OR myocardial infarction [Tiab] OR
heart failure [Tiab] OR cardiac failure [Tiab] OR
left ventricular dysfunction [Tiab] OR acute coro-
nary syndrome [Tiab] OR cerebrovascular disease
[Tiab] OR coronary heart disease [Tiab] OR sud-
den cardiac death [Tiab] OR cardiovascular mortal-
ity [Tiab] OR coronary heart disease [Tiab] OR
cardiorenal [Tiab] OR stroke [MeSH] OR myocar-
dial infarction [MeSH] OR heart failure [MeSH]
OR ventricular dysfunction, left [MeSH] OR acute
coronary syndrome [MeSH] OR death, sudden,
cardiac [MeSH]
2. coxibs OR COX2 inhibitors OR cyclooxygenase 2
Inhibitors OR nsaids OR non-steroidal anti-
inflammatory OR “Anti-Inflammatory Agents,
Non-Steroidal” [Mesh] OR phenylbutazone OR
mofebutazone OR oxyphenbutazone OR clofezone
OR kebuzone OR indometacin OR sulindac OR
tolmetin OR zomepirac OR aceclofenac OR diclo-
fenac OR alclofenac OR bumadizone OR etodolac
OR lonazolac OR fentiazac OR acemetacin OR
difenpiramide OR oxametacine OR proglumetacin
OR ketorolac OR bufexamac OR indometacin,
combinations OR diclofenac, combinations OR pir-
oxicam OR tenoxicam OR droxicam OR lornoxi-
cam OR meloxicam OR ibuprofen OR naproxen
OR ketoprofen OR fenoprofen OR fenbufen OR
benoxaprofen OR suprofen OR pirprofen OR flurbi-
profen OR indoprofen OR tiaprofenic acid OR oxa-
prozin OR ibuproxam OR dexibuprofen OR
flunoxaprofen OR alminoprofen OR dexketoprofen
OR ibuprofen, combinations OR ketoprofen, combi-
nations OR mefenamic acid OR tolfenamic acid OR
flufenamic acid OR meclofenamic acid OR cele-
coxib OR rofecoxib OR valdecoxib OR parecoxib
OR etoricoxib OR lumiracoxib OR nabumetone
OR niflumic acid OR azapropazone OR glucos-
amine OR benzydamine OR glycosaminoglycan
polysulfate OR proquazone OR orgotein OR nime-
sulide OR feprazone OR diacerein OR morniflumate
OR tenidap OR oxaceprol OR chondroitin sulfate
OR feprazone
3. cohort studies OR cohort OR epidemiologic meth-
ods OR case-control studies OR (case AND con-
trol) OR risk OR incidence
4. letter [Publication Type] OR editorial [Publication
Type] OR comment [Publication Type]
5. #1 AND #2 AND #3
6. #5 NOT #4
7. #6 AND limits Entrez Date from 1990/01/01 to
2008/11/30; Humans, English
APPENDIX B
QUALITY ASSESSMENT ACCORDING TO
THE NEWCASTLE–OTTAWA SCALE
Case–Control Studies
Among selected studies in the systematic review of
stroke risk and NSAID use, there were two nested
case–control studies for inclusion in the meta-analysis.
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The results of the quality evaluation according to the
Newcastle–Ottawa Scale of these studies are presented
in the table below for the selection, comparability, and
exposure dimensions. The two studies scored the max-
imum numbers of starts for selection, comparability,
and exposure.
Newcastle–Ottawa Scale Score
Study's
first author
Publication
year
Selection
(max. = 4)
Comparability
(max. = 2)
Exposure
(max. = 3)
Bak 2003 **** ** ***
Andersohn 2006 **** ** ***
Cohort Studies
A total of four cohort studies were selected for in-
clusion in the meta-analysis, and their quality was
evaluated. The results of this evaluation are presented
in the table below for the selection, comparability,
and outcome dimensions. Two studies scored four stars,
and three scored two stars for selection. For compara-
bility and outcome, all four studies scored the maxi-
mum (two and three stars, respectively).
Newcastle–Ottawa Scale Score
Study's
first author
Publication
year
Selection
(max. = 4)
Comparability
(max. = 2)
Outcome
(max. = 3)
Solomon 2006 *** ** ***
Abraham 2007 *** ** ***
Haag 2008 **** ** ***
Roumie 2008 **** ** ***
APPENDIX C
The SOS Project: list of research institutions
• Erasmus Universitair Medisch Centrum Rotterdam
(EMC)
• Fundació IMIM (FIMIM)
• University of Nottingham (UNOTT)
• Università Degli Studi di Milano-Bicocca (UNIMIB)
• Research Triangle Institute (RTI-HS)
• Universitaet Bremen (Uni-HB)
• The Research Institute of the McGill University
Health Centre (RI-MUHC)
• Azienda Ospedaliera di Padova (AOPD)
• PHARMO Coöperation UA (PHARMO)
• Université Victor Segalen Bordeaux II (UB2)
• Azienda Sanitaria Locale della provincia di Cremona
(ASL/OSSIF)
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